Skip to content

Vitamin D Supplementation in Vitamin D Deficient Obese Children During Weight-loss Program

Long-term Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Children During Integrated Weight-loss Program - a Double Blind Placebo Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02828228
Enrollment
200
Registered
2016-07-11
Start date
2016-02-29
Completion date
2019-02-28
Last updated
2016-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

obesity, weight loss, vitamin D deficiency, body composition

Brief summary

1. Analyze the influence of vitamin D supplementation in obese children during weight-loss program on BMI, body composition and bone mineral density. 2. Analyze the influence of vitamin D supplementation on the risk profile of obesity-related complications, namely impaired tolerance of glucose, insulin resistance, dyslipidemia and arterial hypertension, in obese children participating in weight-loss program. 3. Analyze the prevalence of vitamin D deficiency among obese children. 4. Analyze the risk factors of vitamin D deficiency in obese children (age, gender, pubertal status).

Detailed description

The study will be conducted as a continuation and development of 6-10-14 for Health program. The first phase of the program, financed by the municipality of Gdansk, was conducted in 2011-2013. The program comprised of screening and survey conducted among all 6-, 10- and 14-year-old children attending primary and grammar schools. A total of 18 162 children (including 7 448 6-year olds, 6 720 10-year olds and 3 994 14-year olds) were examined. A group of children with risk factors of civilization-related diseases (overweight and obesity defined according to BMI percentile charts. was identified on the basis of the screening. This group included 2 798 (16.32%) children, among them 9.17% of 6-years of age, 19.30% of 10-years and 20.48% of 14-years). All these children were qualified to intervention and education program. A total of 1 627 children qualified on the basis of screening eventually took part in the first edition of the program. A total of 4 meetings with participating children and their caregivers were scheduled during the 12-month-long education and intervention program: at enrollment, and 3, 6 and 12 months thereafter. The meetings had form of individual consultations with various specialists. The first visit included complex medical examination, discussion on a health status of a child, interpretation of laboratory findings, and consultations with dietician, psychologist and physical education specialist. After consulting all the specialists involved in the program, individual protocol of health intervention was developed for every child. The objectives of the intervention included modification of diet, increasing health activity level and strengthening of health-seeking behaviors of child's family members. Adherence to the protocol and achieved results were evaluated during follow-up meetings with the specialists, and constituted the basis for development of individualized intervention plans for subsequent months. The preliminary evaluation of the program effects was conducted in the group of 300 participants. The average percentile of BMI at enrollment to the program and after 12 months of participation amounted to 92.96 and 88.83, respectively. Participation in the program was reflected by a significant decrease in BMI percentile (p=0.0001), as well as by a significant drop off in fat mass content measured by bioelectrical impedance, from 39.0% to 31.4% (p=0.0001). On the basis of these findings, the municipality of Gdansk decided to support the program for 2014-2016. The experiment will follow a pattern of double blind randomized study. The enrolled subjects will be randomly assigned to one of the two groups: Group 1 - weight-loss program for 52 weeks + vitamin D 1200 (IU) daily for 26 weeks Group 2 - weight-loss program for 52 weeks +placebo daily for 26 weeks Visit I: enrollment: * medical history, physical examination * interpretation of laboratory findings (the tests conducted during screening + concentration of vitamin D), * anthropometric evaluation and analysis of body composition (bioimpedance method) * consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention * Kasch Pulse Recovery Test * determination of hs-C-reactive protein, Interleukin 6, chemerin and adiponectin concentrations in blood samples obtained during screening * informing parents about the objectives and protocol of the study * obtaining written informed consent for participation in the study * randomization to GROUP I or II * densitometry (DXA) - within one week after enrollment Visit II: after 13 weeks: * medical history, physical examination * anthropometric evaluation and analysis of body composition (bioimpedance method) * consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention Within a week prior to Visit III - obtaining blood (ca. 5 ml) for laboratory testing (complete blood count, lipid profile, hs-C-reactive protein, oral glucose tolerance test, insulin, Interleukin 6, adiponectin and chemerin concentrations Visit III: after 26 weeks: * medical history, physical examination * interpretation of laboratory findings * anthropometric evaluation and analysis of body composition (bioimpedance method) * consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention * obtaining blood for laboratory testing * termination of active compound/placebo administration Visit IV: after 52 weeks: * medical history, physical examination * anthropometric evaluation and analysis of body composition (bioimpedance method) * consultation of dietician, psychologist and specialist of physical activity, and defining detailed protocol of intervention * densitometry (DXA) - within one week after terminating the study

Interventions

DRUGVitamin D 1200 IU

Vitamin D 1200 IU once a day for 26 weeks

DRUGPlacebo

placebo once a day for 26 weeks

Sponsors

Nutricia Foundation
CollaboratorOTHER
University Clinical Centre, Gdansk
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
6 Years to 14 Years
Healthy volunteers
No

Inclusion criteria

* overweight (BMI between the 85th and 95th percentile) or obesity (BMI \> 95th percentile), identified on the basis of anthropometric parameters * blood concentration of 25(OH)D3 \< 30 ng/ml * written consent of legal guardians

Exclusion criteria

* Chronic conditions (asthma or allergies, inflammatory diseases of connective tissue, gastrointestinal disorders, diseases of kidneys and liver, disorders of bone metabolism) * Contraindications to administration of vitamin D * Administration of any preparation containing vitamin D, calcium, or steroid hormones during 3 months preceding the study

Design outcomes

Primary

MeasureTime frameDescription
Bone mineral density12 monthsIncrease in bone mineral density during weight-loss program and vitamin D supplementation

Secondary

MeasureTime frameDescription
Arterial blood pressure12 monthsChange in blood pressure afer weight-loss and vitamin D supplementation
Lipid profile12 monthsChange of lipid profile after weight-loss and vitamin D supplementation
Oral Glucose Tolerance Test12 monthsChange of biochemical parameters after weight-loss and vitamin D supplementation
Blood level of vitamin D12 monthsChanges in blood level of vitamin D after supplementation
BMI (kg/m2)12 monthsChange of BMI during 12-months weight loss-program and supplementation of vitamin D
Fat mass (kg)12 monthsChange in fat free mass during 12-months weight-loss programme and supplementation of vitamin D
Chemerin12 monthsChange in chemerin level

Countries

Poland

Contacts

Primary ContactMagdalena Słominska-Frączek, MD,
fraczek@gumed.edu.pl694844420
Backup ContactAgnieszka Jankowska, MD, PhD
ajankowska@gumed.edu.pl48606335246

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026